Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 2010. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding their interests in the company's Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a disclosure of share ownership changes and does not contain financial performance data.
Material Changes
The material change disclosed is the acquisition of Ordinary shares by specific company personnel on August 10, 2010, at a price of £11.63 per share through the Company's Share Reward Plan. The transactions involved both personal contributions (partnership element) and company contributions (matching element).
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the share price of £11.63 per Ordinary share on August 10, 2010.
- Confirm the specific number of shares acquired by each listed director (ranging from 1 to 11 shares per individual).
- Note that the transactions were executed via the Share Reward Plan, involving both personal and company matching contributions.
- Understand that this filing does not reflect the company's operational or financial performance for the period.